Non-Hodgkin Lymphoma News

• Many Common, Deadly Cancers Underfunded by Nonprofits Many common, deadly cancers are underfunded by nonprofit organizations; these cancers affect parts of the body that are stigmatized, and this may be contributing, say researchers.
  Medscape Medical News, July 2019
• U.S. Judge to Slash $80 Million Roundup Jury Verdict-Court Hearing A U.S. judge on Tuesday said he would reduce an $80 million damage award against Bayer AG to $50 million or less in the case of a man who blamed his cancer on glyphosate-based weed killer Roundup.
  Reuters Health Information, July 2019
• Austrian Parliament Backs EU's First Total Ban of Weedkiller Glyphosate Austria's lower house of parliament passed a bill on Tuesday banning all uses of the weedkiller glyphosate, the first time a European Union country has taken such strong action against the chemical over concerns that it can cause cancer.
  Reuters Health Information, July 2019
• IWMF 2019Living Harmoniously With Incurable Cancer Diagnosed with cancer at age 44, Lise Wise hesitated to go to the support meeting recommended to her because she expected to find sick people who had no hair and no eyebrows, but she found more.
  Medscape Medical News, June 2019
• IWMF 2019Lymphoma Control Better Goal Than Remission Drugs used to treat lymphoplasmacytic lymphoma can have adverse effects, so lowering therapeutic targets might help, delegates heard at the International Waldenstrom's Macroglobulinemia Forum.
  Medscape Medical News, June 2019
• EHA 2019Novel Drug Targets Lymphoma Cells' 'Don't Eat Me' Signal The first-in-class agent Hu5F9 is a macrophage immune checkpoint inhibitor and, when added onto rituximab, shows potentially long-lasting efficacy in patients with relapsed and refractory lymphoma.
  Medscape Medical News, June 2019
• IWMF 2019New Lymphoma Drugs Build on BTK Inhibitor Success Life expectancy for patients with Waldenstrom's macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.
  Medscape Medical News, May 2019
• IWMF 2019Patients With Rare Lymphoma Describe Divergent Experiences Some people are treated aggressively while others watch and wait until symptoms appear; three will describe their experiences at the upcoming Waldenstrom's Macroglobulinemia forum.
  Medscape Medical News, May 2019
• Cemiplimab and Talazoparib Head Toward Approval in the EU Both drugs have received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use, which is the first step in obtaining marketing approval in the European Union.
  International Approvals, April 2019
• Novel CAR T-Cell Approach Reduces Toxicities, Retains Efficacy The modified molecule for the anti-CD19 CAR T-cell therapy shows signs of reducing the risk for severe cytokine release syndrome while maintaining efficacy.
  Medscape Medical News, April 2019
• For Rare, Difficult Cancer, New Drug Is a 'Major Advance' Tagraxofusp, the first-ever drug for blastic plasmacytoid dendritic-cell neoplasm, is being called a major advance. Data are now published in the New England Journal of Medicine.
  Medscape Medical News, April 2019
• Pesticide Exposure Linked to Worse Outcomes in Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) patients exposed to pesticides on the job have worse overall survival (OS) and event-free survival (EFS) and are less likely to respond to treatment, according to new findings.
  Reuters Health Information, April 2019
• Promising Results in Mice Prompt Human Trial of Novel Lymphoma Vaccine An in situ vaccine (ISV) combined with immune stimulants and radiotherapy showed efficacy in mice, prompting a phase 1 trial of patients with advanced indolent non-Hodgkin's lymphoma (INHL), researchers say.
  Reuters Health Information, April 2019
• BSH 2019ITP and B-cell Lymphoma Feature in Latest BSH Guidance Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.
  Medscape News UK, April 2019
• Health Canada Plans to Suspend Allergan's Breast Implant License Health Canada said on Thursday it was advising Allergan Plc of the regulator's plans to suspend the license for the Botox-maker's Biocell breast implants, after a review regarding the risk of a rare cancer linked to breast implants.
  Reuters Health Information, April 2019
• Umbralisib Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma Umbralisib, an investigational oral inhibitor of PI3K-delta, has significant activity against relapsed/refractory marginal-zone lymphoma (MZL) and manageable side effects, according to early results from an ongoing phase 2b trial.
  Reuters Health Information, April 2019
• Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.
  Reuters Health Information, April 2019
• Rituximab Fails to Improve Symptoms in ME/CFS New findings in treating myalgic encephalomyselitis/chronic fatigue syndrome (ME/CFS) contradict previous observations and preliminary trial results; illness heterogeneity was cited as a research challenge.
  Medscape Medical News, April 2019
• U.S. Jury Says Bayer Must Pay $80 Mln to Man in Roundup Cancer Trial A U.S. jury on Wednesday awarded $80 million to a man who claimed his use of Bayer AG's glyphosate-based weed killer Roundup caused his cancer, in the latest legal setback for the company facing thousands of similar lawsuits.
  Reuters Health Information, March 2019
• More Info on Risks of Breast Implants Needed, Says FDA Panel A 2-day meeting highlighted the risk for a rare lymphoma, described as a 'man-made cancer,' and heard calls for a ban on certain products, but advisers also highlighted lack of data.
  Medscape Medical News, March 2019